Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-0.28 |
-0.69 |
-0.41 |
-146.43% |
2024-03-21 |
2023-12 |
0 |
-0.55 |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.33 |
-0.31 |
0.02 |
6.06% |
2023-08-14 |
2023-06 |
-0.35 |
-0.28 |
0.07 |
20.00% |
2023-05-11 |
2023-03 |
-0.29 |
-0.4 |
-0.11 |
-37.93% |
2023-03-16 |
2022-12 |
-0.25 |
-0.29 |
-0.04 |
-16.00% |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-03-06 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2021-03-21 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2020-05-14 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-13 |
BIRX DEBORAH L. |
Chief Executive Officer |
260.00K |
Stock Award(Grant) |
2018-03-21 |
COOK JEREMY CURNOCK |
Director |
0.00 |
Purchase |
2015-10-05 |
DRAPEAU LOUIS C |
Director |
10.00K |
Purchase |
2017-12-07 |
GRINT PAUL C |
Chief Executive Officer |
599.00 |
Stock Award(Grant) |
2022-03-30 |
INNOVIVA, INC. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2016-12-28 |
KIRK RANDAL JOE |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bank of America Corporation |
634.44K |
723.27K |
1.76% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
193.68K |
220.80K |
0.54% |
2023-06-29 |
Edgewood Management Llc |
100.00K |
114.00K |
0.28% |
2023-06-29 |
Renaissance Technologies, LLC |
62.40K |
71.13K |
0.17% |
2023-06-29 |
Vanguard Group Inc |
59.89K |
68.27K |
0.17% |
2023-06-29 |
Blackrock Inc. |
24.42K |
27.83K |
0.07% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
184.68K |
210.54K |
0.51% |
2023-06-29 |
Vanguard Extended Market Index Fund |
55.93K |
63.76K |
0.15% |
2023-08-30 |
iShares Micro Cap ETF |
24.11K |
83.42K |
0.07% |
2023-05-30 |
Fidelity Extended Market Index Fund |
15.51K |
20.78K |
0.04% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
4.98K |
6.67K |
0.01% |
2023-06-29 |
EQ Advisors Trust-1290 VT Micro Cap Port |
2.00K |
2.28K |
0.01% |
Split |
Date |
1 : 14 |
2019-05-10 |
1 : 10 |
2017-04-25 |
1 : 50 |
2015-08-07 |
1 : 10 |
2006-05-11 |
0.1 : 1 |
2006-05-10 |